News Katie Matt 3/4/25 News Katie Matt 3/4/25 Boosting CAR T-cell Efficacy to Increase Cancer Cure Rates Read More News Katie Matt 2/21/24 News Katie Matt 2/21/24 Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies Read More News Katie Matt 8/8/23 News Katie Matt 8/8/23 Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001 Read More News Rhodesia Jackson 11/7/22 News Rhodesia Jackson 11/7/22 Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001 Read More News Rhodesia Jackson 6/23/21 News Rhodesia Jackson 6/23/21 Aleta Biotherapeutics and Cancer Research UK collaborate to advance blood cancer therapy into the clinic Read More
News Katie Matt 3/4/25 News Katie Matt 3/4/25 Boosting CAR T-cell Efficacy to Increase Cancer Cure Rates Read More
News Katie Matt 2/21/24 News Katie Matt 2/21/24 Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies Read More
News Katie Matt 8/8/23 News Katie Matt 8/8/23 Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001 Read More
News Rhodesia Jackson 11/7/22 News Rhodesia Jackson 11/7/22 Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001 Read More
News Rhodesia Jackson 6/23/21 News Rhodesia Jackson 6/23/21 Aleta Biotherapeutics and Cancer Research UK collaborate to advance blood cancer therapy into the clinic Read More
